Shares of Neose Pharmaceuticals took a nasty hit on Tuesday after the FDA raised questions about its stability test for its experimental anemia therapy. Questions about the test for determining how well NE-180 keeps in storage will further delay a trial for the therapy. The agency originally put the trial on hold last summer with a request for preclinical and manufacturing information. Impatient investors slashed 16 percent of Neose's share price yesterday in retaliation for the latest delay.
- here's the AP report on Neose